News

Review top news and interview highlights from the week ending May 27, 2022.

The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.

The vice president of neuroscience at Sangamo Therapeutics discussed identifying novel capsids with improved neuronal transduction to the CNS.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief scientific officer of Sangamo Therapeutics discussed the first-in-human STEADFAST trial.

All study participants met criteria to remain off enzyme replacement therapy through 104 weeks after treatment.

NeoCart was originally developed by the company Histogenics.

The director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.

A final analysis of the pivotal HOPE-B study was presented at ASGCT 2022.

The senior investigator from NINDS discussed findings investigating serious AEs across different trials.

The positive opinion was based on findings from studies conducted in Taiwan.

The clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.

In an interview with CGTLive, study primary investigator Donald Kohn, MD, discussed the safety and efficacy observed in the phase 2 trial.

Review top news and interview highlights from the week ending May 20, 2022.

The director of the leukodystrophy service at Mass Gen discussed progress dosing in the phase 1/2 trial.

Motor and pulmonary function have stabilized or improved in participants treated with SGT-001.

Findings from a preclinical study, which are in contrast with the current biphasic recovery model, have implications for both HSC transplantation and gene therapy.

Investigators from Seattle Children’s Hospital found that engineered T-cell regulatory products demonstrated significant suppression of effector T cells.

The trial met its primary efficacy end point, and participants reported improvements in quality-of-life factors such as outlook on the future and feelings about having hemophilia.

The interim study results presented at ASGCT 2022 likely represent the longest follow-up data to date for the largest cohort of infants with XSCID treated with lentiviral vector gene therapy.

Safety and efficacy data suggest this to be a feasible and clinically meaningful treatment for a patient population with high disease burden.

Catch up on the latest news and announcements in cell and gene therapies presented at the annual ASGCT meeting.

Multiple insertions were observed in affected participants, including insertions in the MECOM and PRDM16 genes.

One patient with metastatic pancreatic cancer remains alive on maintenance chemotherapy 3 years after treatment.

Data from 2 patients dosed in the Imagine-1 clinical trial were presented in a late breaking session at ASGCT 2022.

Investigators are evaluating the safety, tolerability and preliminary efficacy of CT-0508 in patients with solid tumors and HER2 overexpression.

Investigators found a dose-dependent increase in CAART cell persistence.

Trial sponsors Pfizer, Sarepta, Genethon, and Solid Biosciences organized a group of experts to investigate shared serious AEs.